Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

458.12 +7.14 (+1.58%)
Streaming Delayed Price Updated: 10:57 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
Shares of the growing biotech company have doubled in three years. 
Via The Motley Fool
2 Biotech Stocks to Buy in May
You could buy these in any month, really. 
Via The Motley Fool
3 High-Flying Stocks That Could Soar Even More
The momentum should continue for Eli Lilly, Novo Nordisk, and Vertex Pharmaceuticals. 
Via The Motley Fool
Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity
Via Benzinga
SLB, First Solar And 2 Other Stocks Insiders Are Selling
Via Benzinga
Walmart, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'
Walmart Inc. reported a "really strong" quarter, with e-commerce sales surging 21%. Adjusted EPS was 60 cents. 
Via Benzinga
Should you consider NASDAQ:VRTX for quality investing?
VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) Exhibits Quality Stock Traits. Here's Why. 
Via Chartmill
Vertex Pharmaceuticals's Options Frenzy: What You Need to Know
Via Benzinga
A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics
Via Benzinga
The 2030 Millionaire’s Club: 3 Biotech Stocks to Buy Now
With interest cuts on the horizon, it's a prime time to consider these high-risk-high-reward biotech stocks to buy. 
Via InvestorPlace
Vertex to Participate in Upcoming June Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating
On Thursday, biotech Halozyme Therapeutics stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier. 
Via Investor's Business Daily
Is CRISPR Stock Going to $95? 1 Wall Street Analyst Thinks So.
How much would you pay for a stock that might earn $25 a year in six years? 
Via The Motley Fool
Jennifer Schneider Elected to Vertex Board of Directors
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Pfizer, Freeport-McMoRan, Vertex Pharmaceuticals And A Major Tech Stock On CNBC's 'Final Trades'
Pfizer is looking to build on the success of its COVID-19 vaccine rollout by introducing a direct-to-consumer medicines platform. 
Via Benzinga
Exposures COVID-19
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating
On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79. 
Via Investor's Business Daily
3 Cheap Biotech Stocks to Buy Now: May 2024
Many of these cheap biotech stocks are on their way to achieving FDA approval for their drugs to enter the market. 
Via InvestorPlace
Exposures Product Safety
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 10 Years
Via Benzinga
Vertex Pharmaceuticals Is Racing Towards a New Blockbuster: Why the Stock Is a Smart Buy
The biotech's shares dropped following its latest quarterly update, but that shouldn't matter to long-term investors. 
Via The Motley Fool
2 Unbelievable Growth Stocks You Can Buy and Hold for the Next Decade
These companies are raking in profits at astonishing clips. 
Via The Motley Fool
Stock Market Moves Toward Highs; Arista, Toast, Palantir Key Earnings Movers: Weekly Review
Big earnings winners and losers continued. 
Via Investor's Business Daily
Will the Biotech Sector Shift From Lagger to Leader?
The biotech sector has experienced a significant rally after bouncing off uptrend support and is now consolidating near major SMAs. 
Via MarketBeat
Topics ETFs
Investors seeking growth at a reasonable cost should explore NASDAQ:VRTX.
While growth is established for NASDAQ:VRTX, the stock's valuation remains reasonable. 
Via Chartmill
5 Reasons Vertex Pharmaceuticals Is a Screaming Buy on the Dip
New drugs in development and a lack of significant patent cliffs ahead make this a great pharma stock to buy now and hold over the long run. 
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
Markets In A Minute - "A Lack Of Further Progress"
May's FOMC meeting left the Fed Funds Rate unchanged. JOLTS showed fewer job openings with increased layoffs. April's job report disappointed, adding only 175k jobs and seeing higher unemployment.... 
Via Talk Markets
Topics Economy Workforce
Exposures Interest Rates Layoff
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
US Stocks Eye Fourth Positive Session Despite Hawkish Fed Remarks; Disney, Palantir Tumble; Treasury Yields Fall: What's Driving Markets Tuesday?
Wall Street experienced a quiet session during morning trading on Tuesday, influenced by a lack of significant economic data and minimal updates on earnings from major large-cap companies. 
Via Benzinga
Topics Economy
Exposures Interest Rates
VRTX Stock Earnings: Vertex Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
VRTX stock results show that Vertex Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Vertex Pharmaceuticals (VRTX) Q1 2024 Earnings Call Transcript
VRTX earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Vertex Beats First-Quarter Expectations, But Shares Stay Flat On Reiterated Outlook
Vertex Pharmaceuticals beat first-quarter sales and earnings forecasts. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.